share_log

Further Weakness as Hainan Haiyao (SZSE:000566) Drops 7.7% This Week, Taking Three-year Losses to 51%

Further Weakness as Hainan Haiyao (SZSE:000566) Drops 7.7% This Week, Taking Three-year Losses to 51%

海南海藥(深交所股票代碼:000566)本週下跌7.7%,使三年跌幅達到51%,進一步疲軟
Simply Wall St ·  2023/12/20 17:05

If you are building a properly diversified stock portfolio, the chances are some of your picks will perform badly. Long term Hainan Haiyao Co., Ltd. (SZSE:000566) shareholders know that all too well, since the share price is down considerably over three years. Regrettably, they have had to cope with a 51% drop in the share price over that period. On top of that, the share price is down 7.7% in the last week.

如果你正在建立一個適當多元化的股票投資組合,那麼你的某些選擇很可能會表現不佳。從長遠來看,海南海藥股份有限公司(深交所股票代碼:000566)的股東對此非常了解,因爲股價在三年內大幅下跌。遺憾的是,在此期間,他們不得不應對股價下跌51%的局面。最重要的是,上週股價下跌了7.7%。

Since Hainan Haiyao has shed CN¥493m from its value in the past 7 days, let's see if the longer term decline has been driven by the business' economics.

由於海南海藥在過去7天內貶值了4.93億元人民幣,讓我們看看長期下跌是否是由該企業的經濟推動的。

See our latest analysis for Hainan Haiyao

查看我們對海南海藥的最新分析

Given that Hainan Haiyao only made minimal earnings in the last twelve months, we'll focus on revenue to gauge its business development. Generally speaking, we'd consider a stock like this alongside loss-making companies, simply because the quantum of the profit is so low. For shareholders to have confidence a company will grow profits significantly, it must grow revenue.

鑑於海南海藥在過去十二個月中僅實現了最低收益,我們將重點關注收入來衡量其業務發展。總的來說,我們會將這樣的股票與虧損公司一起考慮,這僅僅是因爲利潤量太低了。要使股東有信心公司大幅增加利潤,就必須增加收入。

In the last three years Hainan Haiyao saw its revenue shrink by 11% per year. That is not a good result. With revenue in decline, and profit but a dream, we can understand why the share price has been declining at 15% per year. Having said that, if growth is coming in the future, now may be the low ebb for the company. We'd be pretty wary of this one until it makes a profit, because we don't specialize in finding turnaround situations.

在過去的三年中,海南海藥的收入每年減少11%。這不是一個好結果。收入下降,利潤只是夢想,我們可以理解爲什麼股價每年下跌15%。話雖如此,如果未來出現增長,那麼現在可能是公司的低潮。在它盈利之前,我們會非常警惕,因爲我們不擅長尋找轉機情況。

The graphic below depicts how earnings and revenue have changed over time (unveil the exact values by clicking on the image).

下圖描繪了收入和收入隨着時間的推移而發生的變化(點擊圖片顯示確切的數值)。

earnings-and-revenue-growth
SZSE:000566 Earnings and Revenue Growth December 20th 2023
SZSE: 000566 2023年12月20日收益和收入增長

This free interactive report on Hainan Haiyao's balance sheet strength is a great place to start, if you want to investigate the stock further.

如果你想進一步調查海南海藥資產負債表實力,這份關於海南海藥資產負債表實力的免費互動報告是一個很好的起點。

A Different Perspective

不同的視角

It's good to see that Hainan Haiyao has rewarded shareholders with a total shareholder return of 0.7% in the last twelve months. That certainly beats the loss of about 2% per year over the last half decade. We generally put more weight on the long term performance over the short term, but the recent improvement could hint at a (positive) inflection point within the business. While it is well worth considering the different impacts that market conditions can have on the share price, there are other factors that are even more important. For example, we've discovered 1 warning sign for Hainan Haiyao that you should be aware of before investing here.

很高興看到海南海藥在過去十二個月中向股東提供了0.7%的總股東回報率。這無疑超過了過去五年中每年約2%的損失。我們通常更看重短期內的長期表現,但最近的改善可能暗示業務出現了(積極的)轉折點。儘管市場狀況可能對股價產生的不同影響值得考慮,但還有其他因素更爲重要。例如,我們發現了海南海藥的1個警告信號,在這裏投資之前你應該注意這個信號。

If you would prefer to check out another company -- one with potentially superior financials -- then do not miss this free list of companies that have proven they can grow earnings.

如果你想看看另一家公司——一家財務狀況可能優異的公司——那麼千萬不要錯過這份已經證明自己可以增加收益的公司的免費名單。

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on Chinese exchanges.

請注意,本文引用的市場回報反映了目前在中國交易所交易的股票的市場加權平均回報率。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對這篇文章有反饋嗎?對內容感到擔憂?直接聯繫我們。 或者,給編輯團隊 (at) simplywallst.com 發送電子郵件。
Simply Wall St 的這篇文章本質上是籠統的。我們僅使用公正的方法提供基於歷史數據和分析師預測的評論,我們的文章並非旨在提供財務建議。它不構成買入或賣出任何股票的建議,也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意,我們的分析可能不會考慮最新的價格敏感型公司公告或定性材料。華爾街只是沒有持有上述任何股票的頭寸。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論